Stocks · News reference

Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $59

Aug 5, 2026, 6:18 PMBenzinga Newsdesk

Truist Securities analyst Gregory Renza maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from $63 to $59.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 19, 2026, 10:03 AMBenzinga Newsdesk
IDEAYA Biosciences Enters Clinical Collaboration With Roche's Genentech To Evaluate The Efficacy And Safety Of IDE892, Its Investigational MTA-Cooperative PRMT5 Inhibitor, In Combination With GDC-7035, Genentech's KRAS G12D Inhibitor, In Patients With Pancreatic Ductal Adenocarcinoma
Collaboration to to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class MTA-cooperative PRMT5 inhibitor, in combination with GDC-7035 (RG6620), Genentech's KRAS G12D inhibitor,
Read original at benzinga
IDYA RHHBY
BenzingaAug 5, 2026, 1:20 PMBenzinga Newsdesk
Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60
Wedbush analyst Robert Driscoll maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and raises the price target from $58 to $60.
Read original at benzinga
IDYA
BenzingaAug 4, 2026, 10:11 AMBenzinga Newsdesk
IDEAYA Biosciences Q2 EPS $(1.22) Misses $(1.09) Estimate, Sales $8.857M Beat $5.015M Estimate
IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(1.09) by 11.93 percent. This is a 38.64 percent decrease over losses of $(0.88) per share
Read original at benzinga
IDYA